Topical Niacinamide: What the Skin Trials Actually Show

Key points

• Niacinamide is vitamin B3 and is used in cosmetics as a skin-conditioning ingredient. The human evidence for topical use is real but modest: mostly small trials of 27 to 80 people lasting 4 to 12 weeks.
• The most consistent results are for acne (comparable to 1% clindamycin gel in two trials), barrier function and facial pigmentation. Evidence for rosacea is thin.
• The claim that niacinamide “stimulates endogenous ceramide synthesis” rests mainly on one 2000 paper from a cosmetics company laboratory, using cultured human keratinocytes plus a skin measurement. We rate it partly supported.
• The skin-cancer prevention results come from oral nicotinamide, not creams. They were positive in one trial of 386 people and null in a trial of 158 transplant recipients.
• In the US it is regulated as a cosmetic ingredient, which needs no FDA approval before sale.

What niacinamide is

Niacinamide, also called nicotinamide, is the amide form of vitamin B3. It is a component of the coenzymes NAD and NADP [20]. Cosmetic safety reviewers classify it as a skin and hair conditioning agent [14].

It is not the same molecule as niacin (nicotinic acid). The 2005 Cosmetic Ingredient Review (CIR) assessed both together and judged them toxicologically similar [14]. This article covers niacinamide only.

What the human trials found

The table lists the trials we opened. All are human studies of topical products unless stated. Study design and size come from the published abstracts.

Area	Study	Design and size	Reported result
Acne	Shalita 1995 [4]	Double-blind, 76 people, 8 weeks, 4% nicotinamide gel vs 1% clindamycin gel	82% improved with nicotinamide vs 68% with clindamycin on physician global evaluation; difference not significant (P = 0.19)
Acne	Khodaeiani 2013 [5]	Randomized, double-blind, 80 people, same two gels	Both lowered acne grade (nicotinamide 5.93 to 2.08, clindamycin 5.70 to 2.03 at week 8); no between-group difference
Acne	Morganti 2011 [19]	Multicentre, 12 weeks, nicotinamide with phosphatidylcholine emulsion vs clindamycin	Combination slightly better than clindamycin; nicotinamide effect cannot be separated
Melasma	Navarrete-Solis 2011 [7]	Double-blind split-face, 27 women, 8 weeks, 4% niacinamide vs 4% hydroquinone, sunscreen used	Both improved; colour measures did not differ; “good to excellent” improvement 44% vs 55%
Facial aging	Bissett 2005 [9]	Double-blind split-face, 50 women, 12 weeks, 5% niacinamide vs vehicle	Fewer fine lines, spots and red blotchiness, better elasticity. Authors worked at Procter & Gamble
Rosacea	Draelos 2005 [10]	Investigator-blind, 50 people, 4 weeks, niacinamide moisturizer	The indexed abstract describes the design but reports no results
Acne with irritation	Tempark 2024 [6]	Split-face, 40 people, 8 weeks, ceramide plus niacinamide moisturizer vs plain cream, alongside benzoyl peroxide and adapalene	More lesion reduction with the moisturizer; the two cannot be separated

Three things limit what these trials can say. They are short, with the longest at 12 weeks. Several test finished products that contain other ingredients, so the niacinamide effect cannot be isolated [6][19]. And a 2022 review of topical melasma treatments, which found niacinamide effective as an adjunct, noted small samples and a lack of recent large studies with long-term follow-up [18].

For pigmentation, a single-arm study of a four-ingredient cream (including niacinamide) in epidermal melasma reported lower severity scores, but with no control group it says little about niacinamide itself [8].

We did not find a large, long-term randomized trial of topical niacinamide for any skin condition. The tazarotene comparison people often reach for is covered in tazarotene vs tretinoin, and a related brightening and redness ingredient in azelaic acid.

The oral nicotinamide skin-cancer trials (not creams)

Oral nicotinamide has been tested for preventing non-melanoma skin cancer. Capsules are a different exposure from a cream, and these results should not be carried over to cosmetics.

• ONTRAC (2015). A phase 3 double-blind trial in Australia randomized 386 people who had at least two non-melanoma skin cancers in the previous 5 years to 500 mg of nicotinamide twice daily or placebo for 12 months [11]. New non-melanoma skin cancers were 23% lower (95% CI 4 to 38; P = 0.02). Actinic keratoses were also lower, and there was no evidence of benefit after treatment stopped [11]. It was funded by Australia’s National Health and Medical Research Council [11].
• ONTRANS (2023). The same group randomized 158 organ-transplant recipients with at least two prior keratinocyte cancers. At 12 months there were 207 new cancers on nicotinamide and 210 on placebo (rate ratio 1.0; 95% CI 0.8 to 1.3). The trial stopped early for poor recruitment [12].
• Meta-analysis (2022). A review of randomized trials found 29 studies with 3,039 patients and pooled five trials (552 patients) for skin cancer, with a rate ratio of 0.50 (95% CI 0.29 to 0.85) and substantial heterogeneity (I2 = 64%). It also found more digestive side effects with nicotinamide [13]. It predates ONTRANS.

The ceramide claim: what the primary study showed

The post at the centre of this check is by @Hoostethics (1 November 2026), which quotes the same account’s 19 October “topical skincare tier list”. In our archived transcription of that list, niacinamide sits in tier A with the note “stimulates endogenous ceramide synthesis” [1]. The mirror we read for the 1 November post (fxtwitter, because X blocks automated access) showed the tier list in summary, and we took the niacinamide line from our archived copy of the text, not from the mirror.

The mechanism is traced to Tanno and colleagues (British Journal of Dermatology, September 2000) [2]. They worked in two systems:

• Cultured normal human keratinocytes. Cells incubated with 1 to 30 micromol/L nicotinamide for 6 days made ceramide 4.1 to 5.5 times faster than controls, measured by labelled serine incorporation. Glucosylceramide rose 7.4-fold, sphingomyelin 3.1-fold, free fatty acids 2.3-fold and cholesterol 1.5-fold. Activity of serine palmitoyltransferase, the rate-limiting enzyme, and the mRNA of its subunits also rose [2].
• Human skin in vivo. The abstract states that topical nicotinamide increased ceramide and free fatty acid levels in the stratum corneum and lowered transepidermal water loss in dry skin. The abstract does not give the number of participants, concentration or duration [2]. The authors were at Kanebo Ltd’s research laboratory; the abstract does not state funding [2].

A later study did not test the mechanism. In 20 healthy volunteers, 28 days of twice-daily niacinamide formulations on the forearm gave lower water loss, thicker stratum corneum and larger, more mature corneocytes. It measured corneocytes and enzyme activity, not ceramide levels [3].

Verdict: partly supported. Cell work shows increased ceramide synthesis, and a human skin measurement from the same paper points the same way. We found no independent human study in what we opened that quantified skin ceramides after niacinamide, so the claim is a plausible mechanism from one lab, not an established one. “Stimulates endogenous ceramide synthesis” is also stronger than the in vivo data we could read.

The same list is assessed tier by tier in our tier-list check. A tweet is a claim, not evidence.

Regulatory status

Dates are when we read each page.

• United States. FDA states that cosmetic products and ingredients, apart from color additives, “do not require FDA approval before they go on the market” (page current 11 September 2024). A product becomes a drug if its marketed intended use is to treat or prevent disease [15]. Under the Modernization of Cosmetics Regulation Act, companies must list products, report serious adverse events within 15 business days and keep safety substantiation records (FDA page updated 29 October 2026) [16]. Niacinamide has no cosmetic-specific limit in the sources we opened. Oral nicotinamide for skin cancer: we did not check any FDA label or listing.
• European Union. Regulation (EC) No 1223/2009 sets a general safety requirement (Article 3), a safety assessment (Article 10) and notification of products (Article 13) [17]. The 2005 CIR report records niacinamide as accepted for cosmetic use in the EU and Japan [14]. We could not open the CosIng entry or confirm whether a Scientific Committee on Consumer Safety opinion exists.
• UK, Germany: not checked.

“Research use only” does not apply: niacinamide is a common cosmetic and food ingredient, not a research peptide.

Risks and unknowns

• Topical safety. The CIR panel found niacinamide non-toxic at levels far above cosmetic use. Clinical tests reported no stinging up to 10%, no irritation in use tests up to 5%, and no sensitization or photosensitization [14]. In the acne trials, Khodaeiani reported no major side effects [5]. In the melasma trial, side effects occurred in 18% with niacinamide and 29% with hydroquinone [7].
• Animal and cell findings. In animal and cell studies cited by the CIR, niacinamide itself was not carcinogenic in mice, but it modified tumour induction by some carcinogens in either direction, and it caused chromosome aberrations in hamster cells at higher concentrations [14]. These do not map directly to human cosmetic use.
• Oral nicotinamide. The meta-analysis found more digestive adverse effects [13]. ONTRAC found no noteworthy differences in adverse events over 12 months [11]. People with transplants or prior skin cancer are a different population from general cosmetic users. We could not open the European Food Safety Authority tolerable upper intake level for nicotinamide, so we do not quote one.
• Not studied. Long-term topical safety beyond 12 weeks in trials, use in pregnancy and children, and independent replication of the ceramide result.

Frequently asked questions

Does niacinamide work for acne? Two double-blind trials, of 76 and 80 people over 8 weeks, found a 4% nicotinamide gel comparable to a 1% clindamycin gel [4][5]. Neither showed a significant difference, and both are small and short.

Does niacinamide increase ceramides in skin? In cultured human keratinocytes it increased ceramide synthesis several-fold, and the same 2000 paper reports higher stratum corneum ceramide in vivo [2]. We found no independent human replication that measured ceramides.

Is oral nicotinamide the same as a niacinamide cream? No. The skin-cancer trials used capsules in people with a history of skin cancer [11][12]. They say nothing about creams.

Is niacinamide FDA approved? In the US it is regulated as a cosmetic ingredient, and cosmetics do not need FDA approval before sale [15]. Whether a specific drug listing exists for oral nicotinamide was not checked.

Sources

1. @Hoostethics on X, post of 2026-11-01 quoting the 2026-10-19 “topical skincare tier list”. https://x.com/Hoostethics/status/2116976569034092805 (text read through the fxtwitter mirror because X blocks automated access; niacinamide line taken from the archived transcription in our sources folder) ; original topical skincare tier list of 2026-10-19: https://x.com/Hoostethics/status/2112214865779806696
2. Tanno O et al., “Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier”, British Journal of Dermatology (September 2000). https://pubmed.ncbi.nlm.nih.gov/10971324/
3. Mohammed D et al., “Influence of niacinamide containing formulations on the molecular and biophysical properties of the stratum corneum”, International Journal of Pharmaceutics (30 January 2013). https://pubmed.ncbi.nlm.nih.gov/23220080/
4. Shalita AR et al., “Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris”, International Journal of Dermatology (June 1995). https://pubmed.ncbi.nlm.nih.gov/7657446/
5. Khodaeiani E et al., “Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris”, International Journal of Dermatology (August 2013). https://pubmed.ncbi.nlm.nih.gov/23786503/
6. Tempark T et al., “Efficacy of ceramides and niacinamide-containing moisturizer versus hydrophilic cream in combination with topical anti-acne treatment”, Journal of Cosmetic Dermatology (May 2024). https://pubmed.ncbi.nlm.nih.gov/38299457/
7. Navarrete-Solis J et al., “A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma”, Dermatology Research and Practice (2011). https://pubmed.ncbi.nlm.nih.gov/21822427/
8. Crocco EI et al., “A novel cream formulation containing nicotinamide 4%, arbutin 3%, bisabolol 1%, and retinaldehyde 0.05% for treatment of epidermal melasma”, Cutis (November 2015). https://pubmed.ncbi.nlm.nih.gov/26682557/
9. Bissett DL et al., “Niacinamide: A B vitamin that improves aging facial skin appearance”, Dermatologic Surgery (July 2005). https://pubmed.ncbi.nlm.nih.gov/16029679/
10. Draelos ZD et al., “Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea”, Cutis (August 2005). https://pubmed.ncbi.nlm.nih.gov/16209160/
11. Chen AC et al., “A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention”, New England Journal of Medicine (22 October 2015). https://pubmed.ncbi.nlm.nih.gov/26488693/
12. Allen NC et al., “Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients”, New England Journal of Medicine (2 March 2023). https://pubmed.ncbi.nlm.nih.gov/36856616/
13. Mainville L et al., “Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis”, Journal of Cutaneous Medicine and Surgery (May-June 2022). https://pubmed.ncbi.nlm.nih.gov/35134311/
14. Cosmetic Ingredient Review Expert Panel, “Final report of the safety assessment of niacinamide and niacin”, International Journal of Toxicology (2005). https://pubmed.ncbi.nlm.nih.gov/16596767/
15. U.S. FDA, “Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)” (current as of 2024-09-11). https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
16. U.S. FDA, “Modernization of Cosmetics Regulation Act of 2022 (MoCRA)” (updated 2026-10-29). https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
17. European Union, Regulation (EC) No 1223/2009 on cosmetic products (only article headings 3, 10 and 13 were visible to us). https://eur-lex.europa.eu/eli/reg/2009/1223/oj/eng
18. González-Molina V et al., “Topical Treatments for Melasma and Their Mechanism of Action”, Journal of Clinical and Aesthetic Dermatology (May 2022). https://pubmed.ncbi.nlm.nih.gov/35642229/
19. Morganti P et al., “Topical clindamycin 1% vs. linoleic acid-rich phosphatidylcholine and nicotinamide 4% in the treatment of acne: a multicentre-randomized trial”, International Journal of Cosmetic Science (October 2011). https://pubmed.ncbi.nlm.nih.gov/21668835/
20. Gehring W, “Nicotinic acid/niacinamide and the skin”, Journal of Cosmetic Dermatology (April 2004). https://pubmed.ncbi.nlm.nih.gov/17147561/

This article is information, not medical advice.